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Abstract 
Introduction 
Prescription drug abuse presents a significant challenge to the management of postoperative 
pain. Pain control amongst the opioid addicted patient can be especially challenging.  We aimed 
to improve pain control after cesarean delivery with enhanced recovery in patients who are on 
buprenorphine medication-assisted therapy for the treatment of opioid addiction. 
Materials and Methods 
We conducted a pilot study by implementing a protocol using liposomal bupivacaine injected at 
the time of cesarean delivery. Patients were then given 500mg oral acetaminophen every 4 hours, 
800mg oral ibuprofen every 8 hours and 0.3mg IV buprenorphine every 6 hours as needed. 
Patients’ maintenance dosing of buprenorphine was divided into doses throughout the day.  In 
addition, patients were ambulated 4 hours after surgery and had their catheters removed from 
their bladder as soon as they could safely ambulate.  Eleven patients were prospectively recruited 
and then compared to a retrospective sample of seventeen patients. 
Results 
Patients in the treatment group reported 27% lower pain scores (p<0.05) with 55% and 100% 
achieving a mean pain score 3 and 4 or less, respectively (p<0.05).  Patients who were in the 
treatment group utilized 51% less breakthrough IV buprenorphine with 45% declining IV 
buprenorphine, however these did reach statistical significance.  Hospital charges were reduced 
by $1,589 (p<0.01). 
Discussion 
Our enhanced recovery protocol is an effective alternative to traditional pain control and is 
associated with a significant reduction in both pain scores and use of breakthrough IV 
buprenorphine as well as lower charges. 
Keywords 
 
buprenorphine, ERAS, pain control, cesarean delivery, liposomal bupivacaine 
Introduction 
Prescription drug abuse creates a significant problem in the United States. With 41.5 overdoses 
per 100,000, West Virginia has among the highest overdose rates in the country.1 Buprenorphine 
is an approved form of medication-assisted therapy and is recommended for the treatment of 
addiction in pregnancy.2 Pain control for this patient population can be especially challenging, as 
literature regarding this subject is lacking.  Further complicating pain management in this 
population is the high opioid maintenance dose utilized by this population.  Using standard 
opioid conversion ratio of 1mg sublingual buprenorphine to 10mg oral morphine,3,4 a patient 
taking 16mg daily of sublingual buprenorphine is already taking 160mg opioid daily.  For 
comparison, this is the same as taking 21 oxycodone 5mg tablets, 8mg of IV hydromorphone, 
53mg of IV morphine or 533mcg of IV fentanyl daily.3,4 Cesarean delivery accounts for 31% of 
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all deliveries, making it one of the most common operations on reproductive age women.5 This 
therefore necessitates evaluation of post-cesarean pain protocols. 
Certain protocols have been developed specifically to help patients recover more rapidly after 
surgery. Enhanced Recovery after Surgery (ERAS) protocols utilize multimodal pain control and 
local anesthesia combined with early feeding, ambulation and catheter removal to expedite 
patient recovery.6-12 Several studies have shown that ERAS protocols improve patient pain 
control and increase patient satisfaction while decreasing opioid use.6-12  Liposomal bupivacaine 
is a formulation of the local anesthetic bupivacaine that has been encapsulated by lipids in order 
to increase the effective duration of the drug by several days.13 One study found that using 
liposomal bupivacaine along with ERAS protocols decreased length of stay following a cesarean 
delivery without any increase in adverse events.6  
There is a paucity of data evaluating any manner of pain control after cesarean delivery in 
patients who struggle with opioid addiction, let alone those on buprenorphine medication-
assisted therapy.  Data evaluating liposomal bupivacaine is limited to the aforementioned study.   
We hypothesize that implementation of an ERAS protocol that utilizes liposomal bupivacaine at 
the time of surgery will improve pain control and decrease the use of IV buprenorphine for 
breakthrough pain in patients undergoing a cesarean delivery who are in opioid-addiction 
recovery programs that utilize buprenorphine for medication-assisted therapy.   
Materials and Methods 
We conducted an ambispective pilot study to evaluate postoperative pain management strategies.  
This started with a retrospective analysis of the current standard of care. At our institution, 
patients who undergo scheduled cesarean delivery receive spinal anesthesia consisting of 13mg 
bupivacaine, 10mcg of fentanyl and 0.2mg morphine.  Currently, in addition to the On-Q® and 
continuing current home maintenance buprenorphine dose as scheduled, patients receive IV 
ketorolac 30mg every 6 hours followed by 10mg oral ketorolac every 6 hours, as well as 0.3mg 
IV buprenorphine every 6 hours as needed.   The On-Q® system utilizes percutaneous catheters 
that infiltrate the abdominal and pelvic cavities with buprenorphine over a 2 to 3 day period.  
After surgery, patients are allowed regular diet 1 hour after surgery.  The catheter is removed 
after 12 to 24 hours and patient is allowed to ambulate 12 hours after surgery.  The retrospective 
analysis included patients within given time period that met inclusion criteria.  
Next, we prospectively implemented an ERAS protocol previously described in gynecologic 
oncology literature.13 This protocol consisted of the spinal anesthesia, as mentioned above, 
followed by 266mg (20mL) diluted into an additional 20 mL of normal saline of liposomal 
bupivacaine injected subcutaneously along the length of the incision at time of skin closure. 
Postoperative pain was controlled with 500mg of oral acetaminophen scheduled every 4 hours, 
800mg of oral ibuprofen every 8 hours and 0.3mg IV buprenorphine every 6 hours as needed for 
breakthrough pain. Maintenance buprenorphine dose was then divided into 4 times daily dosing.  
For example, if a patient takes 16mg daily of buprenorphine then they would receive 4mg every 
6 hours postoperatively. Patients resumed regular diet 1 hour after surgery.  In addition, patients 
were ambulated after 4 hours and the catheter was removed when the patient could safely 
ambulate. 
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We compared the retrospective data, which reflected the standard of care, to the data we 
collected prospectively following the implementation of the ERAS protocol. For the 
retrospective analysis, we included all eligible patients over a 1-year span. To be eligible for 
inclusion in the retrospective group, patients had to be at an age of 18 years or greater, at a 
gestational age of 34 weeks or greater, and have a non-emergent cesarean delivery at Cabell 
Huntington Hospital while being treated for opioid addiction with medication-assisted therapy 
using buprenorphine. For eligibility for inclusion in the prospective group, patients had to meet 
the same criteria as described for the retrospective group.  With informed consent, we recruited a 
prospective group for the implementation of the ERAS protocol over a 6-month period.  Patients 
were excluded from the study if any one of the above-mentioned criteria were not met.  
We then conducted a retrospective evaluation of medical records for several data points. These 
included: patient demographics, medical comorbidities, gravidity, parity, postoperative pain 
scores, postoperative complications, length of stay (LOS), postoperative care charges, and IV 
buprenorphine use during hospitalization. Routine patient care also included the collection of 
urine drug screens. The administration of all postoperative drugs began when the patient left the 
operative suite, as recorded by the nursing staff.   
Mean pain scores served as the primary outcome. On the day of surgery and postoperative days 
1, 2 and 3, the mother-baby nurse recorded pain scores on a Likert scale of 0-10 with 0 
representing no pain and 10 representing severe pain. The goal at our institution was for the 
patient to meet a pain score of 3 or less. Because other institutions use the measure of a pain 
score of 4 or less, both data points were recorded. We also measured several secondary 
outcomes, including the amount of IV buprenorphine used, LOS, nausea and/or vomiting that 
required the use of anti-emetics as well as hospital and pharmacy charges. These charges 
included the cost of the local anesthetic used intraoperatively as well as the charges for 
medications used to control pain and nausea and/or vomiting post operatively. A unique 
identifier was given to every patient. The master code for these identifiers was securely stored on 
a password-protected computer. The retrospective pre-implementation data and the prospective 
post-implementation data was compared using the Fisher Exact test and the Mann Whitney U 
test. Because data collection was recorded as part of routine postpartum documentation, blinding 
of patients, providers, and staff was virtually impossible. However, care was taken to ensure that 
the research staff did not interact with the patient following informed consent, except as 
medically necessary for routine obstetric and gynecological care. Our study protocol was 
approved by the Institutional Review Board who found it to be exempt from full review due to 
the low risk that implementing the protocol posed to the research subjects. Informed consent was 
also waived for those subjects in the retrospective cohort. The authors of this study do not have 
any financial disclosures.  
Results 
Seventeen patients met inclusion criteria and were included in the MARC cohort retrospective 
control group.  Eleven patients met inclusion criteria for the prospective ERAS group for 
analysis.  Due to the low-risk nature of the study, none of the eligible patients declined 
participation in the study.  As shown in Table 1, overall mean age was 30.5 years with a range of 
23-41 years and a standard deviation of 4.5 years.  Mean BMI was 30.9kg/m2 with a range of 20-
42kg/m2 and a standard deviation of 6.3kg/m2. The ERAS group had a higher obesity rate 
(34.0% versus 28.4%, p<0.01), however the distribution among the various classes of obesity 
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were similar.   There were more smokers in the ERAS group 82 versus 71 percent (p<0.05).  All 
patients in both the retrospective and prospective groups were on 8mg of sublingual 
buprenorphine twice daily preoperatively.  Pregnancy demographics, surgical characteristics and 
the comorbidities of hypertension and diabetes mellitus were similar between the groups.  All 
urine drug screens were only appropriately positive for buprenorphine. 
Table 1.  Demographic and Surgical Characteristics (n=28) 
Characteristic    Control (n=17)  ERAS (n=11)  p Value  
Demographic 
 Age(y)    17 [30.9 (29.0-32.9)] 11 [28.4 (26.6-32.8)] 0.50‡ 
 BMI    17 [28.4 (26.1-30.8)] 11 [34.0 (30.3-37.7)] 0.01‡ 
  Normal or overweight 12 (71)   3 (27)   0.07§ 
  Class I and II obesity 4   (24)   5 (45) 
  Morbid Obesity  1   (5)   3 (27) 
Smoking         0.02§ 
  Never   5   (29)   0 (0)     
  Former   0   (0)   2 (18)     
  Current   12 (71)   9 (82)    
Comorbidities 
 Hypertension   3 (18)   4 (36)   0.54§  
  GHTN, Preeclampsia 2 (12)   3 (27) 
  CHTN    1 (6)   1 (9)   
 Diabetes Mellitus   0 (0)   1 (10)              >0.99§   
  Pre-pregnancy  0 (0)   0 (0)      
  Gestational  0 (0)   1 (13) 
Pregnancy Demographics 
 Parity                     >0.99§ 
Primiparous  1   (6)   1   (9)    
  Multiparous  16 (94)   10 (91)  
 EGA at time of delivery  17 [382/7 (375/7-390/7)] 11 [373/7 (352/7-394/7)].     >0.99‡ 
Surgical Characteristics 
 Primary Cesarean Delivery 3 (18)   2 (18)   0.68§ 
 Indication                    >0.99§ 
  Repeat   14 (82)   9 (82) 
  Malpresentation  1   (6)   1 (9) 
  Obstructed Labor  2   (12)   1 (9) 
 Anesthesia                    >0.99§ 
  Spinal   14 (82)   9 (82) 
  Epidural   3   (18)   2 (18) 
Tubal Ligation   6   (40)   6 (50)   0.44§ 
 Birth Weight (g)   17 [3116 (2858-3373)] 11 [2868 (2362-3373)] 0.31‡ 
 EBL (mL)   17 [641 (588-695)] 11 [555 (483-626)] 0.06‡ 
 1 minute APGAR 7 or greater 17 (100)   10 (91)   0.39§ 
Data are n [mean (95% CI)] or n (%) 
‡ Mann-Whitney U Test 
§ Fisher Exact 
GHTN = Gestational hypertension 
CHTN = Chronic hypertension or chronic hypertension with superimposed preeclampsia 
Overall pain scores were 27% lower in the ERAS group (2.95 versus 4.04, p<0.05), as shown in 
Table 2.  100 percent of patients in the ERAS group met the pain score goal of 4 or less versus 
53% in the control group (p<0.05).  Likewise, 55% of the ERAS patients versus 18% of the 
control group (p<0.05) met the pain score goal of 3 or less (odds Ratio 5.6, 95% CI 1.00-31.3).  
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The odds ratio for the pain goal of 4 or less could not be calculated as 100 percent of the ERAS 
group met this goal. 
Table 2.  Primary Outcomes (n=28) 
Characteristic   Control (n=17)  ERAS (n=11)  Change  p Value  
Markers of Effective Pain Control 
Pain Score  
  Day 0   17 [4.37 (2.82-5.93)] 11 [3.82 (1.66-5.98)] - 13%  0.66‡ 
  Day 1   17 [4.77 (3.54-6.00)] 11 [2.77 (1.47-4.07)] - 42%  0.03‡  
  Day 2   17 [4.02 (3.02-5.02)] 11 [3.46 (2.43-4.50)] - 14%  0.46‡  
Day 3   16 [3.03 (1.94-4.12)] 8   [1.81 (0.00-3.63)] - 40%  0.23‡ 
 Mean  17 [4.04 (3.31-4.76)] 11 [2.95 (2.26-3.63)] - 27%  0.04‡  
 
Achieved Pain Goal (≤3) 3 (18)   6  (55)     0.05§ 
Achieved Pain Goal (≤4) 9 (53)   11(100)     0.007§ 
 
Markers of Ineffective Pain Control 
 Days with Mean Score > 5         0.29§ 
  1 or more days 8 (47)   7 (64)   
  2 or more days 6 (35)   1 (9) 
  3 or more days 1 (6)   0 (0) 
 
Days with Mean Score > 7         0.70§ 
  1 or more days 2 (12)   0 (0)   
  2 or more days 1 (6)   0 (0) 
   
Persistent pain with mean pain score of: 
  5 or greater 3 (18)   0 (0)     0.21§  
  7 or greater 1 (6)   0 (0)     0.61§ 
Data are n [mean (95% CI)] or n (%) 
‡ Mann-Whitney U Test 
§ Fisher Exact 
 
Similarly, ERAS patients had a lower incidence of days with significant pain, 5 or higher, at 47 
versus 64 percent (p=0.29) and lower incidence of days with a severe pain score, 7 or higher, at 0 
versus 12 percent (p=0.70), although these did not reach statistical significance.  Likewise, 
ERAS subjects had a lower proportion of those who reported persistent pain of 5 or greater (0 
versus 18 percent, p=0.21) and persistent severe pain of 7 or greater (0 versus 6 percent, p=0.61), 
however these did not reach statistical significance.  
 
As shown in Table 3, overall IV buprenorphine use was 51% lower in the ERAS group when 
compared to the control group, however, this did not reach statistical significance (0.53mg versus 
1.08mg, p=0.18).  Although not statistically significant, patients were more likely to go without 
IV buprenorphine entirely (45 versus 24 percent, p=0.22).  The range of opioid use in the control 
group was 0mg to 4.2mg with a standard deviation of 1.3mg.  The range of opioid use in the 
ERAS group was 0mg to 1.8mg with a standard deviation of 0.7mg.  While not statistically 
significant, patients were less likely to need a breakthrough antiemetic at 9 versus 29 percent 
(p=0.21).  Day 2 discharge rate was higher in the ERAS group at 36 versus 6 percent, but 
likewise did not reach statistical significance (p=0.15).  Pharmacy charges were $603 lower 
($1581 versus $2184, p<0.01).  Overall hospital charges were $1589 lower ($10106 versus 
$11695, p<0.01).   
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Table 3.  Secondary Outcomes Patients (n=28) 
Characteristic   Control (n=17)  ERAS (n=11)  Change  p Value  
Breakthrough Narcotic Use (mg IV Buprenorphine) 
 Day 0    17 [0.23 (0.09-0.37)] 11[0.25 (0.04-0.44)] + 7%  0.89‡ 
 Day 1    17 [0.34 (0.13-0.54)] 11[0.14 (0.00-0.28)] - 59%  0.16‡ 
 Day 2    17 [0.35 (0.12-0.59)] 11[0.05 (0.00-0.18)] - 85%  0.07‡ 
 
Total by Day 2  17 [0.92 (0.45-1.40)] 11[0.44 (0.10-0.78)] - 53%  0.16‡ 
 
Day 3    16 [0.16 (0.02-0.29)] 7  [0.02 (0.04-0.09)] - 83%  0.15‡ 
 
Total    17 [1.08 (0.47-1.68)] 11[0.53 (0.14-0.93)] - 51%  0.18‡ 
    
Declined IV Buprenorphine 4 (24)   5 (45)     0.22§ 
 
Day 2 Discharge    1 (6)   4 (36)     0.15§ 
  
Needed Breakthrough Antiemetic 5 (29)   1 (9)     0.21§ 
 
Postpartum Charges ($)   
Pharmacy Charges 17 [2184 (1922-2447)] 11[1581 (1345-1817)] - $603  0.003‡  
R&B Charges  17 [9510 (9137-9883)] 11[8524 (7394-9655)] - $986  0.04‡ 
Total Charges   17 [11695 (11276-12114)] 11[10106 (8883-11328)] - $1589   0.004‡ 
Data are n [mean (95% CI)] or n (%) 
‡ Mann-Whitney U Test 
§ Fisher Exact 
R&B = Room and board charges for both mother and infant in the postpartum period 
 
None of the patients abandoned the protocol to return to traditional pain control methods.  None 
of the patients in either the retrospective or prospective groups took narcotics aside from 
buprenorphine.  With regard to the liposomal bupivacaine, none of the patients reported allergy, 
wound infection, injection site reaction or any other complications. Despite early ambulation and 
early catheter removal, we did not have any adverse events such as urinary retention or falls. All 
patients completed the study as no patients withdrew consent.   
 
Discussion 
Treating opioid addicted patients represents a special challenge. The goal is to avoid excess 
narcotics to prevent relapse while still adequately treating postsurgical pain so as to help prevent 
patients from self-medicating.  Our protocol was associated with a 27% reduction in mean pain 
scores.  Patients in the ERAS group were 5.6 times more likely to reach the pain goal of 3 or less 
with 100% of the patients reaching a mean pain score of 4 or less despite all of the control 
patients using the On-Q® bupivacaine system.  We observed a lower incidence of persistent 
severe pain in the ERAS, however this did not reach statistical significance.   
Our protocol appeared to be associated with dramatic reductions in IV buprenorphine use at 
51%, however this did not reach statistical significance.  This statistic was underpowered for this 
outcome due to the large variability. A secondary Mann-Whitney test showed to have 80% 
power with an alpha of 0.05 to detect an opioid reduction of 51% was 130 patients per group due 
to the variability in IV buprenorphine use, which was not feasible for this pilot study.  Given the 
price difference between the On-Q® system and liposomal bupivacaine, and lower utilization of 
45
White et al.: Improving postoperative pain control with enhanced recovery
Published by Marshall University's Joan C. Edwards School of Medicine, 2018
  
expensive intravenous acetaminophen and intravenous buprenorphine, this protocol was 
associated with a marked reduction in pharmacy charges as well as overall hospital charges.   
This study examines a unique population in that 29-73% of the subjects are obese, 26-36% of 
patients are tobacco users, and the subjects come from an area highly addicted to opioids. This is 
the first study to address pain management in patients who struggle with addiction and who are 
on maintenance therapy.  This study is among the first that evaluates the safety and efficacy of 
liposomal bupivacaine after cesarean delivery. The higher proportion of patients who use 
tobacco in the ERAS group may have increased the IV buprenorphine use in the ERAS group, as 
tobacco use is associated with higher levels of narcotic use.15 However, its relationship to 
buprenorphine utilization is unclear and likely did not significantly alter our results.  While the 
intrinsic validity characteristics demonstrate the lack of randomization, a preponderance of the 
patient-specific characteristics that increase surgical difficulty were similar among the groups.   
Our study design is a unique ambispective design containing both a retrospective, before 
intervention, and a prospective, after intervention, component. Although blinding was impossible 
due to the nature of the ERAS protocol intervention, a significant amount of attention was given 
to avoiding bias in the data collection process. The language used to obtain informed consent 
was carefully chosen to avoid artificial lowering of pain scores due to patient bias. To protect 
against bias from the research staff, we took care to avoid interacting with the research subjects 
beyond providing their necessary and routine care. To ensure accuracy of pain measurements, 
the nurses were instructed to record pain scores the same way for all patients. In order to avoid 
artificially lowering pain scores, all patients had similar quantities of opioids offered to them. 
Due to the heavily Caucasian population that our facility serves, we were unable to draw any 
meaningful conclusion regarding the effect of the ERAS protocol on minorities.    
Our study is a pilot study, with a relatively small sample (n=28); a larger and sufficiently 
powered study would require a multi-year and multi-center approach.  Patients who underwent 
surgery earlier in the day would logically have a longer postoperative day 0 and thus use more 
opioids.  However, this discrepancy would have a limited impact as an additional few hours of 
postoperative time would not account for the significant difference seen between the groups.  
Our study was not designed, nor intended to compare the efficacy of On-Q® and liposomal 
bupivacaine, rather it was designed to compare a pain management protocol that utilizes 
liposomal bupivacaine to a pain management protocol that utilizes On-Q®.   
Liposomal bupivacaine with an abdominal binder, scheduled oral acetaminophen and ibuprofen 
along with intravenous buprenorphine as needed for breakthrough pain are a safe alternative to 
traditional methods for patients who are undergoing treatment for opioid addiction with 
buprenorphine after non-emergent cesarean delivery after 34 weeks.  Our protocol appears to be 
associated with a 27 percent reduction in pain scores and 51 percent reduction in IV 
buprenorphine use.  This study shows the promise of liposomal bupivacaine and enhanced 
recovery protocols in reducing pain and opioid use postoperatively. Further prospective and 
larger clinical trials are warranted. 
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